** Hansoh Pharmaceutical 3692.HK drops as much as 17.7% to HK$31.74, lowest level since July 14, leading slide in HK-listed biotech and pharmaceuticals shares

** The U.S. has been discussing severe restrictions on Chinese medicines, the New York Times reported on Wednesday, citing a draft executive order

** Stock of InnoCare 9969.HK, WuXi Biologics 2269.HK, WuXi Apptec 2359.HK, Sino Biopharmaceutical 1177.HK, Beigene 6160.HK and CSPC Pharmacedutical 1093.HK fall between 3.8% and 7%

** In China, CSI Brand Name Drug Index .CSI931440 falls 1.9%

** In Hong Kong, Hang Seng Biotech Index .HSHKBIO drops 3.4%, Hang Seng Healthcare Index .HSHCI declines 2.9%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))